Clouds across the new dawn for clinical, diagnostic and biological data : accelerating the development, delivery and uptake of personalized medicine
© 2023 Walter de Gruyter GmbH, Berlin/Boston..
Growing awareness of the genetic basis of disease is transforming the opportunities for improving patient care by accelerating the development, delivery and uptake of personalised medicine and diseases diagnostics. This can mean more precise treatments reaching the right patients at the right time at the right cost. But it will be possible only with a coherent European Union (EU) approach to regulation. For clinical and biological data, on which the EU is now legislating with its planned European Health Data Space (EHDS), it is crucial that the design of this new system respects the constraints also implicit in the testing which generates data. The current EHDS proposal may fail to meet this requirement. It risks being over-ambitious, while taking insufficient account of the demanding realities of data access in daily practice and current economics/business models. It is marred by imprecision and ambiguity, by overlaps with other EU legislation, and by lack of clarity on funding. This paper identifies key issues where legislators should ensure that the opportunities are not squandered by the adoption of over-hasty or ill-considered provisions that jeopardise the gains that could be made in improved healthcare.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:10 |
|---|---|
| Enthalten in: |
Diagnosis (Berlin, Germany) - 10(2023), 4 vom: 01. Nov., Seite 356-362 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Horgan, Denis [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Business models |
|---|
| Anmerkungen: |
Date Completed 29.11.2023 Date Revised 20.03.2024 published: Electronic-eCollection Citation Status MEDLINE |
|---|
| doi: |
10.1515/dx-2023-0022 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM355415089 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM355415089 | ||
| 003 | DE-627 | ||
| 005 | 20240320233051.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1515/dx-2023-0022 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1337.xml |
| 035 | |a (DE-627)NLM355415089 | ||
| 035 | |a (NLM)37036891 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Horgan, Denis |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Clouds across the new dawn for clinical, diagnostic and biological data |b accelerating the development, delivery and uptake of personalized medicine |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 29.11.2023 | ||
| 500 | |a Date Revised 20.03.2024 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 Walter de Gruyter GmbH, Berlin/Boston. | ||
| 520 | |a Growing awareness of the genetic basis of disease is transforming the opportunities for improving patient care by accelerating the development, delivery and uptake of personalised medicine and diseases diagnostics. This can mean more precise treatments reaching the right patients at the right time at the right cost. But it will be possible only with a coherent European Union (EU) approach to regulation. For clinical and biological data, on which the EU is now legislating with its planned European Health Data Space (EHDS), it is crucial that the design of this new system respects the constraints also implicit in the testing which generates data. The current EHDS proposal may fail to meet this requirement. It risks being over-ambitious, while taking insufficient account of the demanding realities of data access in daily practice and current economics/business models. It is marred by imprecision and ambiguity, by overlaps with other EU legislation, and by lack of clarity on funding. This paper identifies key issues where legislators should ensure that the opportunities are not squandered by the adoption of over-hasty or ill-considered provisions that jeopardise the gains that could be made in improved healthcare | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a in vitro diagnostics legislation | |
| 650 | 4 | |a European Health Data Space (EHDS) | |
| 650 | 4 | |a business models | |
| 650 | 4 | |a clinical trials | |
| 650 | 4 | |a diagnostics | |
| 650 | 4 | |a healthcare data | |
| 650 | 4 | |a policy | |
| 650 | 4 | |a regulation | |
| 650 | 4 | |a uptake | |
| 700 | 1 | |a Capoluongo, Ettore |e verfasserin |4 aut | |
| 700 | 1 | |a Dube, France |e verfasserin |4 aut | |
| 700 | 1 | |a Trapani, Dario |e verfasserin |4 aut | |
| 700 | 1 | |a Malapelle, Umberto |e verfasserin |4 aut | |
| 700 | 1 | |a Rovite, Vita |e verfasserin |4 aut | |
| 700 | 1 | |a Omar, Muhammad Imran |e verfasserin |4 aut | |
| 700 | 1 | |a Alix-Panabières, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Rutkowski, Piotr |e verfasserin |4 aut | |
| 700 | 1 | |a Bayle, Arnaud |e verfasserin |4 aut | |
| 700 | 1 | |a Hackshaw, Allan |e verfasserin |4 aut | |
| 700 | 1 | |a Hofman, Paul |e verfasserin |4 aut | |
| 700 | 1 | |a Subbiah, Vivek |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Diagnosis (Berlin, Germany) |d 2014 |g 10(2023), 4 vom: 01. Nov., Seite 356-362 |w (DE-627)NLM250185180 |x 2194-802X |7 nnns |
| 773 | 1 | 8 | |g volume:10 |g year:2023 |g number:4 |g day:01 |g month:11 |g pages:356-362 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1515/dx-2023-0022 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 10 |j 2023 |e 4 |b 01 |c 11 |h 356-362 | ||